Nurix Therapeutics, Inc. NRIX Issuance costs related to equity financing included in accrued expenses and other current liabilities
Issuance costs related to equity financing included in accrued expenses and other current liabilities at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept nrix:IssuanceCostsRelatedToEquityFinancingIncludedInAccruedExpensesAndOtherCurrentLiabilities.
The official record: Nurix Therapeutics, Inc.’s 10-K, filed January 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s issuance costs related to equity financing included in accrued expenses and other current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s issuance costs related to equity financing included in accrued expenses and other current liabilities?
- Nurix Therapeutics, Inc. (NRIX) reported issuance costs related to equity financing included in accrued expenses and other current liabilities of $92.75K in Q3 2025.
- What does issuance costs related to equity financing included in accrued expenses and other current liabilities mean?
- This represents the costs associated with raising equity capital that have been accrued but not yet paid, reflected within current liabilities. It highlights the short-term financial obligations resulting from financing activities. Monitoring these costs helps investors evaluate the efficiency and expense burden of the company's capital-raising efforts.